nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—SLC47A1—Mitoxantrone—lymphatic system cancer	0.178	0.245	CbGbCtD
Imatinib—SLC22A2—Cytarabine—lymphatic system cancer	0.0799	0.11	CbGbCtD
Imatinib—SLC22A1—Cytarabine—lymphatic system cancer	0.0694	0.0957	CbGbCtD
Imatinib—ABCG2—Teniposide—lymphatic system cancer	0.0581	0.0801	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0406	0.056	CbGbCtD
Imatinib—CYP1A2—Carmustine—lymphatic system cancer	0.0356	0.0491	CbGbCtD
Imatinib—CYP3A5—Teniposide—lymphatic system cancer	0.0322	0.0444	CbGbCtD
Imatinib—ABCG2—Vincristine—lymphatic system cancer	0.028	0.0385	CbGbCtD
Imatinib—CYP2C19—Teniposide—lymphatic system cancer	0.026	0.0358	CbGbCtD
Imatinib—CYP2C9—Teniposide—lymphatic system cancer	0.0216	0.0298	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0206	0.0285	CbGbCtD
Imatinib—CYP3A7—Vincristine—lymphatic system cancer	0.0206	0.0285	CbGbCtD
Imatinib—ABCG2—Methotrexate—lymphatic system cancer	0.0169	0.0233	CbGbCtD
Imatinib—CYP3A5—Vincristine—lymphatic system cancer	0.0155	0.0214	CbGbCtD
Imatinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0146	0.0202	CbGbCtD
Imatinib—CYP3A4—Cytarabine—lymphatic system cancer	0.0127	0.0176	CbGbCtD
Imatinib—CYP3A4—Teniposide—lymphatic system cancer	0.0125	0.0173	CbGbCtD
Imatinib—ALB—Methotrexate—lymphatic system cancer	0.0117	0.0161	CbGbCtD
Imatinib—ABCB1—Vincristine—lymphatic system cancer	0.0101	0.0139	CbGbCtD
Imatinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00878	0.0121	CbGbCtD
Imatinib—ABCB1—Methotrexate—lymphatic system cancer	0.0061	0.00841	CbGbCtD
Imatinib—CYP3A4—Vincristine—lymphatic system cancer	0.00604	0.00833	CbGbCtD
Imatinib—Tremor—Carmustine—lymphatic system cancer	0.000204	0.000744	CcSEcCtD
Imatinib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000204	0.000743	CcSEcCtD
Imatinib—Oedema—Bleomycin—lymphatic system cancer	0.000204	0.000743	CcSEcCtD
Imatinib—Erythema—Mitoxantrone—lymphatic system cancer	0.000203	0.000739	CcSEcCtD
Imatinib—Infection—Bleomycin—lymphatic system cancer	0.000203	0.000738	CcSEcCtD
Imatinib—Anaemia—Carmustine—lymphatic system cancer	0.000202	0.000734	CcSEcCtD
Imatinib—Back pain—Vincristine—lymphatic system cancer	0.000202	0.000734	CcSEcCtD
Imatinib—Vomiting—Teniposide—lymphatic system cancer	0.000201	0.000733	CcSEcCtD
Imatinib—Sepsis—Methotrexate—lymphatic system cancer	0.000201	0.000731	CcSEcCtD
Imatinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0002	0.000727	CcSEcCtD
Imatinib—Asthenia—Fludarabine—lymphatic system cancer	0.0002	0.000727	CcSEcCtD
Imatinib—Rash—Teniposide—lymphatic system cancer	0.0002	0.000727	CcSEcCtD
Imatinib—Dermatitis—Teniposide—lymphatic system cancer	0.000199	0.000726	CcSEcCtD
Imatinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000199	0.000723	CcSEcCtD
Imatinib—Headache—Teniposide—lymphatic system cancer	0.000198	0.000722	CcSEcCtD
Imatinib—Pruritus—Fludarabine—lymphatic system cancer	0.000197	0.000717	CcSEcCtD
Imatinib—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000197	0.000716	CcSEcCtD
Imatinib—Back pain—Mitoxantrone—lymphatic system cancer	0.000196	0.000715	CcSEcCtD
Imatinib—Leukopenia—Carmustine—lymphatic system cancer	0.000195	0.000711	CcSEcCtD
Imatinib—Anorexia—Bleomycin—lymphatic system cancer	0.000195	0.000708	CcSEcCtD
Imatinib—Anaemia—Vincristine—lymphatic system cancer	0.000193	0.000701	CcSEcCtD
Imatinib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000191	0.000696	CcSEcCtD
Imatinib—Hypotension—Bleomycin—lymphatic system cancer	0.000191	0.000694	CcSEcCtD
Imatinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00019	0.000693	CcSEcCtD
Imatinib—Convulsion—Carmustine—lymphatic system cancer	0.000189	0.000688	CcSEcCtD
Imatinib—Hypertension—Carmustine—lymphatic system cancer	0.000188	0.000686	CcSEcCtD
Imatinib—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000188	0.000685	CcSEcCtD
Imatinib—Nausea—Teniposide—lymphatic system cancer	0.000188	0.000685	CcSEcCtD
Imatinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000188	0.000683	CcSEcCtD
Imatinib—Vertigo—Vincristine—lymphatic system cancer	0.000187	0.000681	CcSEcCtD
Imatinib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000187	0.00068	CcSEcCtD
Imatinib—Leukopenia—Vincristine—lymphatic system cancer	0.000186	0.000679	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000186	0.000677	CcSEcCtD
Imatinib—Myalgia—Carmustine—lymphatic system cancer	0.000186	0.000676	CcSEcCtD
Imatinib—Chest pain—Carmustine—lymphatic system cancer	0.000186	0.000676	CcSEcCtD
Imatinib—Anxiety—Carmustine—lymphatic system cancer	0.000185	0.000674	CcSEcCtD
Imatinib—Paraesthesia—Bleomycin—lymphatic system cancer	0.000183	0.000667	CcSEcCtD
Imatinib—Malaise—Mitoxantrone—lymphatic system cancer	0.000183	0.000666	CcSEcCtD
Imatinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000182	0.000662	CcSEcCtD
Imatinib—Renal failure acute—Methotrexate—lymphatic system cancer	0.000182	0.000662	CcSEcCtD
Imatinib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000182	0.000661	CcSEcCtD
Imatinib—Convulsion—Vincristine—lymphatic system cancer	0.000181	0.000657	CcSEcCtD
Imatinib—Hypertension—Vincristine—lymphatic system cancer	0.00018	0.000655	CcSEcCtD
Imatinib—Confusional state—Carmustine—lymphatic system cancer	0.00018	0.000654	CcSEcCtD
Imatinib—Oedema—Carmustine—lymphatic system cancer	0.000178	0.000648	CcSEcCtD
Imatinib—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000178	0.000648	CcSEcCtD
Imatinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000177	0.000646	CcSEcCtD
Imatinib—Myalgia—Vincristine—lymphatic system cancer	0.000177	0.000646	CcSEcCtD
Imatinib—Cough—Mitoxantrone—lymphatic system cancer	0.000177	0.000645	CcSEcCtD
Imatinib—Infection—Carmustine—lymphatic system cancer	0.000177	0.000644	CcSEcCtD
Imatinib—Vomiting—Fludarabine—lymphatic system cancer	0.000177	0.000644	CcSEcCtD
Imatinib—Convulsion—Mitoxantrone—lymphatic system cancer	0.000176	0.00064	CcSEcCtD
Imatinib—Rash—Fludarabine—lymphatic system cancer	0.000175	0.000639	CcSEcCtD
Imatinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000175	0.000638	CcSEcCtD
Imatinib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000175	0.000638	CcSEcCtD
Imatinib—Pain—Bleomycin—lymphatic system cancer	0.000175	0.000635	CcSEcCtD
Imatinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000174	0.000635	CcSEcCtD
Imatinib—Headache—Fludarabine—lymphatic system cancer	0.000174	0.000635	CcSEcCtD
Imatinib—Tachycardia—Carmustine—lymphatic system cancer	0.000174	0.000633	CcSEcCtD
Imatinib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000173	0.000629	CcSEcCtD
Imatinib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000173	0.000629	CcSEcCtD
Imatinib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000173	0.000629	CcSEcCtD
Imatinib—Anxiety—Mitoxantrone—lymphatic system cancer	0.000172	0.000627	CcSEcCtD
Imatinib—Lethargy—Methotrexate—lymphatic system cancer	0.000171	0.000624	CcSEcCtD
Imatinib—Discomfort—Mitoxantrone—lymphatic system cancer	0.000171	0.000621	CcSEcCtD
Imatinib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00017	0.000619	CcSEcCtD
Imatinib—Oedema—Vincristine—lymphatic system cancer	0.00017	0.000619	CcSEcCtD
Imatinib—Anorexia—Carmustine—lymphatic system cancer	0.00017	0.000618	CcSEcCtD
Imatinib—Infection—Vincristine—lymphatic system cancer	0.000169	0.000615	CcSEcCtD
Imatinib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000168	0.000612	CcSEcCtD
Imatinib—Confusional state—Mitoxantrone—lymphatic system cancer	0.000167	0.000608	CcSEcCtD
Imatinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000167	0.000607	CcSEcCtD
Imatinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000166	0.000606	CcSEcCtD
Imatinib—Hypotension—Carmustine—lymphatic system cancer	0.000166	0.000606	CcSEcCtD
Imatinib—Oedema—Mitoxantrone—lymphatic system cancer	0.000166	0.000603	CcSEcCtD
Imatinib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000166	0.000603	CcSEcCtD
Imatinib—Nausea—Fludarabine—lymphatic system cancer	0.000165	0.000602	CcSEcCtD
Imatinib—Infection—Mitoxantrone—lymphatic system cancer	0.000165	0.000599	CcSEcCtD
Imatinib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000164	0.000598	CcSEcCtD
Imatinib—Shock—Mitoxantrone—lymphatic system cancer	0.000163	0.000593	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000162	0.000591	CcSEcCtD
Imatinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000162	0.00059	CcSEcCtD
Imatinib—Urticaria—Bleomycin—lymphatic system cancer	0.000162	0.00059	CcSEcCtD
Imatinib—Anorexia—Vincristine—lymphatic system cancer	0.000162	0.00059	CcSEcCtD
Imatinib—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000162	0.000588	CcSEcCtD
Imatinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000161	0.000587	CcSEcCtD
Imatinib—Insomnia—Carmustine—lymphatic system cancer	0.000161	0.000587	CcSEcCtD
Imatinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000161	0.000586	CcSEcCtD
Imatinib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00016	0.000583	CcSEcCtD
Imatinib—Paraesthesia—Carmustine—lymphatic system cancer	0.00016	0.000582	CcSEcCtD
Imatinib—Hypotension—Vincristine—lymphatic system cancer	0.000159	0.000578	CcSEcCtD
Imatinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000159	0.000578	CcSEcCtD
Imatinib—Somnolence—Carmustine—lymphatic system cancer	0.000158	0.000577	CcSEcCtD
Imatinib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000158	0.000575	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000155	0.000564	CcSEcCtD
Imatinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000155	0.000564	CcSEcCtD
Imatinib—Hypotension—Mitoxantrone—lymphatic system cancer	0.000155	0.000563	CcSEcCtD
Imatinib—Insomnia—Vincristine—lymphatic system cancer	0.000154	0.00056	CcSEcCtD
Imatinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000154	0.00056	CcSEcCtD
Imatinib—Paraesthesia—Vincristine—lymphatic system cancer	0.000153	0.000556	CcSEcCtD
Imatinib—Pain—Carmustine—lymphatic system cancer	0.000152	0.000555	CcSEcCtD
Imatinib—Constipation—Carmustine—lymphatic system cancer	0.000152	0.000555	CcSEcCtD
Imatinib—Breast disorder—Methotrexate—lymphatic system cancer	0.000152	0.000552	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000151	0.00055	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000151	0.000549	CcSEcCtD
Imatinib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00015	0.000547	CcSEcCtD
Imatinib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000149	0.000541	CcSEcCtD
Imatinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000148	0.000538	CcSEcCtD
Imatinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000148	0.000537	CcSEcCtD
Imatinib—Somnolence—Mitoxantrone—lymphatic system cancer	0.000147	0.000536	CcSEcCtD
Imatinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000147	0.000534	CcSEcCtD
Imatinib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000147	0.000534	CcSEcCtD
Imatinib—Fatigue—Vincristine—lymphatic system cancer	0.000147	0.000534	CcSEcCtD
Imatinib—Asthenia—Bleomycin—lymphatic system cancer	0.000146	0.000533	CcSEcCtD
Imatinib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000146	0.000531	CcSEcCtD
Imatinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000146	0.00053	CcSEcCtD
Imatinib—Pain—Vincristine—lymphatic system cancer	0.000145	0.000529	CcSEcCtD
Imatinib—Constipation—Vincristine—lymphatic system cancer	0.000145	0.000529	CcSEcCtD
Imatinib—Pruritus—Bleomycin—lymphatic system cancer	0.000144	0.000526	CcSEcCtD
Imatinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000144	0.000524	CcSEcCtD
Imatinib—Eosinophilia—Methotrexate—lymphatic system cancer	0.000144	0.000523	CcSEcCtD
Imatinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000143	0.00052	CcSEcCtD
Imatinib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000142	0.000518	CcSEcCtD
Imatinib—Pain—Mitoxantrone—lymphatic system cancer	0.000142	0.000516	CcSEcCtD
Imatinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000142	0.000516	CcSEcCtD
Imatinib—Abdominal pain—Carmustine—lymphatic system cancer	0.000141	0.000513	CcSEcCtD
Imatinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000141	0.000513	CcSEcCtD
Imatinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000139	0.000506	CcSEcCtD
Imatinib—Pancytopenia—Methotrexate—lymphatic system cancer	0.000138	0.000502	CcSEcCtD
Imatinib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000136	0.000497	CcSEcCtD
Imatinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000136	0.000494	CcSEcCtD
Imatinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000135	0.000493	CcSEcCtD
Imatinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000135	0.000491	CcSEcCtD
Imatinib—Abdominal pain—Vincristine—lymphatic system cancer	0.000134	0.000489	CcSEcCtD
Imatinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000134	0.000489	CcSEcCtD
Imatinib—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000134	0.000486	CcSEcCtD
Imatinib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000132	0.000482	CcSEcCtD
Imatinib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000132	0.000479	CcSEcCtD
Imatinib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000131	0.000478	CcSEcCtD
Imatinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000131	0.000477	CcSEcCtD
Imatinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000131	0.000477	CcSEcCtD
Imatinib—Pneumonia—Methotrexate—lymphatic system cancer	0.00013	0.000474	CcSEcCtD
Imatinib—Vomiting—Bleomycin—lymphatic system cancer	0.00013	0.000472	CcSEcCtD
Imatinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000129	0.000471	CcSEcCtD
Imatinib—Infestation—Methotrexate—lymphatic system cancer	0.000129	0.000471	CcSEcCtD
Imatinib—Depression—Methotrexate—lymphatic system cancer	0.000129	0.00047	CcSEcCtD
Imatinib—Rash—Bleomycin—lymphatic system cancer	0.000129	0.000468	CcSEcCtD
Imatinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000129	0.000468	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000128	0.000467	CcSEcCtD
Imatinib—Asthenia—Carmustine—lymphatic system cancer	0.000128	0.000465	CcSEcCtD
Imatinib—Renal failure—Methotrexate—lymphatic system cancer	0.000127	0.000463	CcSEcCtD
Imatinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000126	0.000459	CcSEcCtD
Imatinib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000126	0.000458	CcSEcCtD
Imatinib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000125	0.000456	CcSEcCtD
Imatinib—Sweating—Methotrexate—lymphatic system cancer	0.000124	0.000452	CcSEcCtD
Imatinib—Haematuria—Methotrexate—lymphatic system cancer	0.000123	0.000449	CcSEcCtD
Imatinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000122	0.000445	CcSEcCtD
Imatinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000122	0.000444	CcSEcCtD
Imatinib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000122	0.000444	CcSEcCtD
Imatinib—Asthenia—Vincristine—lymphatic system cancer	0.000122	0.000444	CcSEcCtD
Imatinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000122	0.000444	CcSEcCtD
Imatinib—Nausea—Bleomycin—lymphatic system cancer	0.000121	0.000441	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000121	0.00044	CcSEcCtD
Imatinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000119	0.000433	CcSEcCtD
Imatinib—Dizziness—Carmustine—lymphatic system cancer	0.000118	0.000429	CcSEcCtD
Imatinib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000117	0.000425	CcSEcCtD
Imatinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000116	0.000424	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000116	0.000423	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—lymphatic system cancer	0.000116	0.000423	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—lymphatic system cancer	0.000115	0.00042	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000115	0.000418	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000114	0.000414	CcSEcCtD
Imatinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000113	0.000412	CcSEcCtD
Imatinib—Vomiting—Carmustine—lymphatic system cancer	0.000113	0.000412	CcSEcCtD
Imatinib—Dizziness—Vincristine—lymphatic system cancer	0.000112	0.000409	CcSEcCtD
Imatinib—Rash—Carmustine—lymphatic system cancer	0.000112	0.000409	CcSEcCtD
Imatinib—Dermatitis—Carmustine—lymphatic system cancer	0.000112	0.000409	CcSEcCtD
Imatinib—Headache—Carmustine—lymphatic system cancer	0.000112	0.000406	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00011	0.0004	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000109	0.000395	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—lymphatic system cancer	0.000108	0.000394	CcSEcCtD
Imatinib—Vomiting—Vincristine—lymphatic system cancer	0.000108	0.000394	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000108	0.000392	CcSEcCtD
Imatinib—Rash—Vincristine—lymphatic system cancer	0.000107	0.00039	CcSEcCtD
Imatinib—Dermatitis—Vincristine—lymphatic system cancer	0.000107	0.00039	CcSEcCtD
Imatinib—Headache—Vincristine—lymphatic system cancer	0.000107	0.000388	CcSEcCtD
Imatinib—Nausea—Carmustine—lymphatic system cancer	0.000106	0.000385	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—lymphatic system cancer	0.000105	0.000384	CcSEcCtD
Imatinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000105	0.000383	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000105	0.000382	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000105	0.000381	CcSEcCtD
Imatinib—Rash—Mitoxantrone—lymphatic system cancer	0.000104	0.00038	CcSEcCtD
Imatinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000104	0.00038	CcSEcCtD
Imatinib—Chills—Methotrexate—lymphatic system cancer	0.000104	0.000379	CcSEcCtD
Imatinib—Headache—Mitoxantrone—lymphatic system cancer	0.000104	0.000378	CcSEcCtD
Imatinib—Alopecia—Methotrexate—lymphatic system cancer	0.000103	0.000374	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—lymphatic system cancer	0.000102	0.00037	CcSEcCtD
Imatinib—Erythema—Methotrexate—lymphatic system cancer	0.000101	0.000368	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000101	0.000368	CcSEcCtD
Imatinib—Nausea—Vincristine—lymphatic system cancer	0.000101	0.000368	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—lymphatic system cancer	9.9e-05	0.00036	CcSEcCtD
Imatinib—Nausea—Mitoxantrone—lymphatic system cancer	9.84e-05	0.000358	CcSEcCtD
Imatinib—Back pain—Methotrexate—lymphatic system cancer	9.78e-05	0.000356	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—lymphatic system cancer	9.53e-05	0.000347	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—lymphatic system cancer	9.38e-05	0.000341	CcSEcCtD
Imatinib—Anaemia—Methotrexate—lymphatic system cancer	9.34e-05	0.00034	CcSEcCtD
Imatinib—Malaise—Methotrexate—lymphatic system cancer	9.12e-05	0.000332	CcSEcCtD
Imatinib—Vertigo—Methotrexate—lymphatic system cancer	9.08e-05	0.000331	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—lymphatic system cancer	9.05e-05	0.000329	CcSEcCtD
Imatinib—Cough—Methotrexate—lymphatic system cancer	8.82e-05	0.000321	CcSEcCtD
Imatinib—Convulsion—Methotrexate—lymphatic system cancer	8.76e-05	0.000319	CcSEcCtD
Imatinib—Chest pain—Methotrexate—lymphatic system cancer	8.61e-05	0.000313	CcSEcCtD
Imatinib—Myalgia—Methotrexate—lymphatic system cancer	8.61e-05	0.000313	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—lymphatic system cancer	8.61e-05	0.000313	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	8.55e-05	0.000311	CcSEcCtD
Imatinib—Discomfort—Methotrexate—lymphatic system cancer	8.5e-05	0.00031	CcSEcCtD
Imatinib—Confusional state—Methotrexate—lymphatic system cancer	8.32e-05	0.000303	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—lymphatic system cancer	8.25e-05	0.0003	CcSEcCtD
Imatinib—Infection—Methotrexate—lymphatic system cancer	8.2e-05	0.000298	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—lymphatic system cancer	8.09e-05	0.000295	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	8.08e-05	0.000294	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—lymphatic system cancer	8.01e-05	0.000292	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—lymphatic system cancer	7.98e-05	0.00029	CcSEcCtD
Imatinib—Anorexia—Methotrexate—lymphatic system cancer	7.86e-05	0.000286	CcSEcCtD
Imatinib—Hypotension—Methotrexate—lymphatic system cancer	7.71e-05	0.000281	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	7.52e-05	0.000274	CcSEcCtD
Imatinib—Insomnia—Methotrexate—lymphatic system cancer	7.46e-05	0.000272	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—lymphatic system cancer	7.41e-05	0.00027	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—lymphatic system cancer	7.36e-05	0.000268	CcSEcCtD
Imatinib—Somnolence—Methotrexate—lymphatic system cancer	7.33e-05	0.000267	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—lymphatic system cancer	7.26e-05	0.000264	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—lymphatic system cancer	7.17e-05	0.000261	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	7.12e-05	0.000259	CcSEcCtD
Imatinib—Fatigue—Methotrexate—lymphatic system cancer	7.11e-05	0.000259	CcSEcCtD
Imatinib—Pain—Methotrexate—lymphatic system cancer	7.06e-05	0.000257	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—lymphatic system cancer	6.8e-05	0.000248	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	6.75e-05	0.000246	CcSEcCtD
Imatinib—Urticaria—Methotrexate—lymphatic system cancer	6.55e-05	0.000239	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—lymphatic system cancer	6.52e-05	0.000237	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—lymphatic system cancer	6.52e-05	0.000237	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—lymphatic system cancer	6.08e-05	0.000221	CcSEcCtD
Imatinib—Asthenia—Methotrexate—lymphatic system cancer	5.92e-05	0.000216	CcSEcCtD
Imatinib—Pruritus—Methotrexate—lymphatic system cancer	5.84e-05	0.000213	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—lymphatic system cancer	5.65e-05	0.000206	CcSEcCtD
Imatinib—Dizziness—Methotrexate—lymphatic system cancer	5.46e-05	0.000199	CcSEcCtD
Imatinib—Vomiting—Methotrexate—lymphatic system cancer	5.25e-05	0.000191	CcSEcCtD
Imatinib—Rash—Methotrexate—lymphatic system cancer	5.2e-05	0.000189	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—lymphatic system cancer	5.2e-05	0.000189	CcSEcCtD
Imatinib—Headache—Methotrexate—lymphatic system cancer	5.17e-05	0.000188	CcSEcCtD
Imatinib—Nausea—Methotrexate—lymphatic system cancer	4.9e-05	0.000178	CcSEcCtD
